

Podcast 2: How Will New DOAC-Specific Reversal Agents Impact Patient Outcomes and Healthcare Delivery?

Chaudhary R, Sharma T, Garg J, et al. Direct oral anticoagulants: a review on the current role and scope of reversal agents. *J Thromb Thrombolysis*. Feb 2020;49(2):271-286. doi:10.1007/s11239-019-01954-2

Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. *N Engl J Med*. Apr 4 2019;380(14):1326-1335. doi:10.1056/NEJMoa1814051

Pollack CV, Jr., Reilly PA, Weitz JI. Dabigatran Reversal with Idarucizumab. *N Engl J Med*. Oct 26 2017;377(17):1691-1692. doi:10.1056/NEJMc1711337

Rawal A, Ardesbna D, Minhas S, Cave B, Ibeguogu U, Khouzam R. Current status of oral anticoagulant reversal strategies: a review. *Ann Transl Med*. Sep 2019;7(17):411. doi:10.21037/atm.2019.07.101

Sheikh-Taha M, Crawley RM. Reversal of Apixaban and Rivaroxaban Using Activated Prothrombin Complex Concentrates in Patients with Major Bleeding. *Am J Cardiovasc Drugs*. Jun 2020;20(3):295-299. doi:10.1007/s40256-019-00383-z

Siegel DM. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. *J Thromb Thrombolysis*. Apr 2015;39(3):395-402. doi:10.1007/s11239-015-1167-9

Siegel DM, Crowther MA. Acute management of bleeding in patients on novel oral anticoagulants. *Eur Heart J*. Feb 2013;34(7):489-498b. doi:10.1093/eurheartj/ehs408

Siegel DM, Curnutte JT, Connolly SJ, et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. *N Engl J Med*. Dec 17 2015;373(25):2413-2424. doi:10.1056/NEJMoa1510991

Steiner T, Weitz JI, Veltkamp R. Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents. *Stroke*. May 2017;48(5):1432-1437. doi:10.1161/strokeaha.116.013343